Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | EDNRB | P24530 | 10/20 | 0.44 |
| ▸ | EDNRA | P25101 | 10/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571027 | 1.00 | KMT2A (0.47) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27805427 | 0.91 | EDNRB (0.44) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL4434013 | 0.90 | KMT2A (0.42) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27805325 | 0.87 | CTSG (0.42) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL27783661 | 0.87 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL570417 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL570658 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL1067633 | 0.85 | EDNRB (0.50) | KMT2AKCNN4EDNRBEDNRANR1I2 | |
| SCHEMBL15991494 | 0.85 | EDNRB (0.46) | KMT2AEDNRBEDNRANR1I2KCNE1 | |
| SCHEMBL28101975 | 0.85 | EDNRB (0.46) | KMT2AEDNRBEDNRANR1I2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | claimed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | claimed |
| US-20140256004-A1 | Process for the Preparation of an Endothelin Receptor Antagonist | CIPLA LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| EP-2768811-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST | Cipla Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013057468-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST | CIPLA LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057468-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN RECEPTOR ANTAGONIST | CIPLA LIMITED (IN) | 2013-04-25 | — | — | WO | disclosed |
| US-8404840-B2 | Process for the preparation of endothelin receptor antagonists | MSN LABORATORIES LIMITED (IL) | 2013-03-26 | — | — | US | disclosed |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | MSN LABORATORIES LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-2350024-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN Laboratories Limited (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010070658-A2 | IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS | MSN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | WO | disclosed |
| EP-2118073-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | Concert Pharmaceuticals Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090069353-A1 | DEUTERIUM-ENRICHED AMBRISENTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069353-A1 | DEUTERIUM-ENRICHED AMBRISENTAN | PROTIA, LLC (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080262006-A1 | Selective endothelin type-a antagonists | CONCERT PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008097468-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262006-A1 | Selective endothelin type-a antagonists | EDNRA, EDNRB, ECE1 | KMT2A 2669/4885KCNN4 1731/4885EDNRB 2/4885 |
| US-20110263854-A1 | Improved Process For The Preparation Of Endothelin Receptor Antagonists | EDNRA, EDNRB, ECE1 | KMT2A 3733/4885KCNN4 844/4885EDNRB 2/4885 |
| US-20140256004-A1 | Process for the Preparation of an Endothelin Receptor Antagonist | EDNRB, EDNRA, AGTR1 | KMT2A 2150/4885KCNN4 1567/4885EDNRB 1/4885 |
| US-20090069353-A1 | DEUTERIUM-ENRICHED AMBRISENTAN | AVPR2, MC2R, AVPR1A | KMT2A 2080/4885KCNN4 877/4885EDNRB 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.